2013
RELATION OF MMPS PROMOTER POLYMORPHISMS TO FACTORS DESCRIBING RHEUMATOID ARTHRITIS
PÁVKOVÁ GOLDBERGOVÁ, Monika; Jolana LIPKOVÁ; Nikolas PÁVEK; Petr NĚMEC; Jindra GATTEROVA et al.Základní údaje
Originální název
RELATION OF MMPS PROMOTER POLYMORPHISMS TO FACTORS DESCRIBING RHEUMATOID ARTHRITIS
Název česky
Vztah mezi promotorovými polymorfismy v genech pro MMP a faktory revmatoidní artritidy.
Autoři
PÁVKOVÁ GOLDBERGOVÁ, Monika; Jolana LIPKOVÁ ORCID; Nikolas PÁVEK; Petr NĚMEC; Jindra GATTEROVA; Miroslav SOUČEK a Anna VAŠKŮ
Vydání
Annual European Congress of Rheumatology EULAR 2013, 2013
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30102 Immunology
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ne
Organizační jednotka
Lékařská fakulta
UT WoS
Klíčová slova česky
revmatoidní artritida, polymorfismus, geny pro MMP
Klíčová slova anglicky
rheumatoid arthritis, polymorpfism, genes for MMPs
Změněno: 26. 2. 2014 13:58, Mgr. Jolana Lipková, Ph.D.
Anotace
V originále
Matrix metalloproteinases (MMPs) as a family of zinc-dependent endopeptidases have been involved in remodelling the extracellular matrix (ECM) not only in rheumatoid arthritis (RA). The promoter polymorphism variants in the MMPs genes can contribute to the onset, progression and severity of RA due to influence of promoter activity leading to altered expression. Objectives: The aim of the study was to examine the relation among polymorphisms and serum levels of selected MMPs (MMP-2, MMP-3, MMP-7, MMP-12, MMP-13), production of auto-antibodies, and factors describing rheumatoid arthritis (RA), such as DAS28 and Total Sharp score. Methods: A total of 156 RA patients according to the ACR criteria, and 100 control subjects were recruited into the study. The measurements of CRP, anti-CCP, presence of rheumatoid factors (RFs), radiographs of both hands with calculation of Total Sharp score (TSS), DAS28 and MMPs (MMP-3, MMP-13) levels in serum were obtained from all RA patients. Results: Complete or almost complete linkage disequilibrium was observed for MMP-2 polymorphisms (-790T/G, -1575A/G, -1306C/T; p < 0.001). All these MMP-2 promoter polymorphisms were related to RF IgG levels (p < 0.05) and RF IgG positivity/negativity (p < 0.01), IL-15 levels (p < 0.05), and in a trend to TNF alpha levels. Higher prevalence of T allele (-790T/G), C allele (-1306C/T) and G allele (-1575A/G) in the RF IgG positive subgroup was observed. The -135G/C MMP-7 polymorphism was related to activity of the disease; the variation was associated to DAS28 score (p < 0.01), TTS (p = 0.05) and HAQ (p = 0.03). A trend of relation between -77G/A MMP-13 polymorphism and TNF alpha levels was found (p = 0.06). No relation of promoter polymorphisms -11715A/6A MMP-3 and -77G/A MMP-13 to MMPs serum levels was proved. The MMP-3 serum level correlated to IL-6 (p = 0.02) and CRP (p = 0.05) levels. Conclusion: In conclusion, we present an association of MMPs gene polymorphisms with the rheumatoid factor IgG, and disease activity.